Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone

Authors: Jeffrey D Altenburg, Andrew A Bieberich, Colin Terry, Kevin A Harvey, Justin F VanHorn, Zhidong Xu, V Jo Davisson, Rafat A Siddiqui

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Breast cancer is a collection of diseases in which molecular phenotypes can act as both indicators and mediators of therapeutic strategy. Therefore, candidate therapeutics must be assessed in the context of multiple cell lines with known molecular phenotypes. Docosahexaenoic acid (DHA) and curcumin (CCM) are dietary compounds known to antagonize breast cancer cell proliferation. We report that these compounds in combination exert a variable antiproliferative effect across multiple breast cell lines, which is synergistic in SK-BR-3 cells and triggers cell signaling events not predicted by the activity of either compound alone.

Methods

Dose response curves for CCM and DHA were generated for five breast cell lines. Effects of the DHA+ CCM combination on cell proliferation were evaluated using varying concentrations, at a fixed ratio, of CCM and DHA based on their individual ED50. Detection of synergy was performed using nonlinear regression of a sigmoid dose response model and Combination Index approaches. Cell molecular network responses were investigated through whole genome microarray analysis of transcript level changes. Gene expression results were validated by RT-PCR, and western blot analysis was performed for potential signaling mediators. Cellular curcumin uptake, with and without DHA, was analyzed via flow cytometry and HPLC.

Results

CCM+DHA had an antiproliferative effect in SK-BR-3, MDA-MB-231, MDA-MB-361, MCF7 and MCF10AT cells. The effect was synergistic for SK-BR-3 (ER- PR- Her2+) relative to the two compounds individually. A whole genome microarray approach was used to investigate changes in gene expression for the synergistic effects of CCM+DHA in SK-BR-3 cells lines. CCM+DHA triggered transcript-level responses, in disease-relevant functional categories, that were largely non-overlapping with changes caused by CCM or DHA individually. Genes involved in cell cycle arrest, apoptosis, inhibition of metastasis, and cell adhesion were upregulated, whereas genes involved in cancer development and progression, metastasis, and cell cycle progression were downregulated. Cellular pools of PPARγ and phospho-p53 were increased by CCM+DHA relative to either compound alone. DHA enhanced cellular uptake of CCM in SK-BR-3 cells without significantly enhancing CCM uptake in other cell lines.

Conclusions

The combination of DHA and CCM is potentially a dietary supplemental treatment for some breast cancers, likely dependent upon molecular phenotype. DHA enhancement of cellular curcumin uptake is one potential mechanism for observed synergy in SK-BR-3 cells; however, transcriptomic data show that the antiproliferation synergy accompanies many signaling events unique to the combined presence of the two compounds.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 21 (6): 1254-1261. Aitken SJ, Thomas JS, Langdon SP, Harrison DJ, Faratian D: Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol. 21 (6): 1254-1261.
2.
go back to reference Bauer K, Parise C, Caggiano V: Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 10: 228- Bauer K, Parise C, Caggiano V: Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer. 10: 228-
3.
go back to reference Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT: An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009, 48 (4): 522-531. 10.1080/02841860802676383.CrossRefPubMed Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B, Mouridsen HT: An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer. Acta Oncol. 2009, 48 (4): 522-531. 10.1080/02841860802676383.CrossRefPubMed
4.
go back to reference Lambein K, Praet M, Forsyth R, Van den Broecke R, Braems G, Matthys B, Cocquyt V, Denys H, Pauwels P, Libbrecht L: Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations. J Clin Pathol. 64 (3): 200-207. Lambein K, Praet M, Forsyth R, Van den Broecke R, Braems G, Matthys B, Cocquyt V, Denys H, Pauwels P, Libbrecht L: Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations. J Clin Pathol. 64 (3): 200-207.
5.
go back to reference Parise CA, Bauer KR, Brown MM, Caggiano V: Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009, 15 (6): 593-602. 10.1111/j.1524-4741.2009.00822.x.CrossRefPubMed Parise CA, Bauer KR, Brown MM, Caggiano V: Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009, 15 (6): 593-602. 10.1111/j.1524-4741.2009.00822.x.CrossRefPubMed
6.
go back to reference Boyd ZS, Wu QJ, O'Brien C, Spoerke J, Savage H, Fielder PJ, Amler L, Yan Y, Lackner MR: Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther. 2008, 7 (12): 3695-3706. 10.1158/1535-7163.MCT-08-0810.CrossRefPubMed Boyd ZS, Wu QJ, O'Brien C, Spoerke J, Savage H, Fielder PJ, Amler L, Yan Y, Lackner MR: Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther. 2008, 7 (12): 3695-3706. 10.1158/1535-7163.MCT-08-0810.CrossRefPubMed
7.
go back to reference Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW: Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep. 23 (5): 1213-1220. Chen XS, Wu JY, Huang O, Chen CM, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW: Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy. Oncol Rep. 23 (5): 1213-1220.
8.
go back to reference Kurt M, Harputluoglu H, Dede DS, Gullu IH, Altundag K: Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer. Breast. 2007, 16 (2): 111-112. 10.1016/j.breast.2007.01.005.CrossRefPubMed Kurt M, Harputluoglu H, Dede DS, Gullu IH, Altundag K: Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer. Breast. 2007, 16 (2): 111-112. 10.1016/j.breast.2007.01.005.CrossRefPubMed
9.
go back to reference Schlotter CM, Vogt U, Allgayer H, Brandt B: Molecular targeted therapies for breast cancer treatment. Breast Cancer Res. 2008, 10 (4): 211-10.1186/bcr2112.CrossRefPubMedPubMedCentral Schlotter CM, Vogt U, Allgayer H, Brandt B: Molecular targeted therapies for breast cancer treatment. Breast Cancer Res. 2008, 10 (4): 211-10.1186/bcr2112.CrossRefPubMedPubMedCentral
10.
go back to reference Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK: Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther. 2007, 6 (7): 1973-1982. 10.1158/1535-7163.MCT-07-0063.CrossRefPubMed Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK: Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther. 2007, 6 (7): 1973-1982. 10.1158/1535-7163.MCT-07-0063.CrossRefPubMed
11.
go back to reference Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10 (6): 515-527. 10.1016/j.ccr.2006.10.008.CrossRefPubMedPubMedCentral Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006, 10 (6): 515-527. 10.1016/j.ccr.2006.10.008.CrossRefPubMedPubMedCentral
12.
go back to reference Stillwell W, Wassall SR: Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids. 2003, 126 (1): 1-27. 10.1016/S0009-3084(03)00101-4.CrossRefPubMed Stillwell W, Wassall SR: Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids. 2003, 126 (1): 1-27. 10.1016/S0009-3084(03)00101-4.CrossRefPubMed
13.
go back to reference Berg JP, Glattre E, Haldorsen T, Hostmark AT, Bay IG, Johansen AF, Jellum E: Longchain serum fatty acids and risk of thyroid cancer: a population-based case-control study in Norway. Cancer Causes Control. 1994, 5 (5): 433-439. 10.1007/BF01694757.CrossRefPubMed Berg JP, Glattre E, Haldorsen T, Hostmark AT, Bay IG, Johansen AF, Jellum E: Longchain serum fatty acids and risk of thyroid cancer: a population-based case-control study in Norway. Cancer Causes Control. 1994, 5 (5): 433-439. 10.1007/BF01694757.CrossRefPubMed
14.
go back to reference Kaizer L, Boyd NF, Kriukov V, Tritchler D: Fish consumption and breast cancer risk: an ecological study. Nutr Cancer. 1989, 12 (1): 61-68. 10.1080/01635588909514002.CrossRefPubMed Kaizer L, Boyd NF, Kriukov V, Tritchler D: Fish consumption and breast cancer risk: an ecological study. Nutr Cancer. 1989, 12 (1): 61-68. 10.1080/01635588909514002.CrossRefPubMed
15.
go back to reference Schloss I, Kidd MS, Tichelaar HY, Young GO, O'Keefe SJ: Dietary factors associated with a low risk of colon cancer in coloured west coast fishermen. S Afr Med J. 1997, 87 (2): 152-158.PubMed Schloss I, Kidd MS, Tichelaar HY, Young GO, O'Keefe SJ: Dietary factors associated with a low risk of colon cancer in coloured west coast fishermen. S Afr Med J. 1997, 87 (2): 152-158.PubMed
16.
go back to reference Vogel VG, McPherson RS: Dietary epidemiology of colon cancer. Hematol Oncol Clin North Am. 1989, 3 (1): 35-63.PubMed Vogel VG, McPherson RS: Dietary epidemiology of colon cancer. Hematol Oncol Clin North Am. 1989, 3 (1): 35-63.PubMed
17.
go back to reference Connolly JM, Gilhooly EM, Rose DP: Effects of reduced dietary linoleic acid intake, alone or combined with an algal source of docosahexaenoic acid, on MDA-MB-231 breast cancer cell growth and apoptosis in nude mice. Nutr Cancer. 1999, 35 (1): 44-49. 10.1207/S1532791444-49.CrossRefPubMed Connolly JM, Gilhooly EM, Rose DP: Effects of reduced dietary linoleic acid intake, alone or combined with an algal source of docosahexaenoic acid, on MDA-MB-231 breast cancer cell growth and apoptosis in nude mice. Nutr Cancer. 1999, 35 (1): 44-49. 10.1207/S1532791444-49.CrossRefPubMed
18.
go back to reference Rose DP: The mechanistic rationale in support of dietary cancer prevention. Prev Med. 1996, 25 (1): 34-37. 10.1006/pmed.1996.0012.CrossRefPubMed Rose DP: The mechanistic rationale in support of dietary cancer prevention. Prev Med. 1996, 25 (1): 34-37. 10.1006/pmed.1996.0012.CrossRefPubMed
19.
go back to reference Rose DP, Connolly JM: Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol. 1999, 15 (5): 1011-1015.PubMed Rose DP, Connolly JM: Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol. 1999, 15 (5): 1011-1015.PubMed
20.
go back to reference Wu M, Harvey KA, Ruzmetov N, Welch ZR, Sech L, Jackson K, Stillwell W, Zaloga GP, Siddiqui RA: Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway. Int J Cancer. 2005, 117 (3): 340-348. 10.1002/ijc.21238.CrossRefPubMed Wu M, Harvey KA, Ruzmetov N, Welch ZR, Sech L, Jackson K, Stillwell W, Zaloga GP, Siddiqui RA: Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway. Int J Cancer. 2005, 117 (3): 340-348. 10.1002/ijc.21238.CrossRefPubMed
21.
go back to reference Blanckaert V, Ulmann L, Mimouni V, Antol J, Brancquart L, Chenais B: Docosahexaenoic acid intake decreases proliferation, increases apoptosis and decreases the invasive potential of the human breast carcinoma cell line MDA-MB-231. Int J Oncol. 36 (3): 737-742. Blanckaert V, Ulmann L, Mimouni V, Antol J, Brancquart L, Chenais B: Docosahexaenoic acid intake decreases proliferation, increases apoptosis and decreases the invasive potential of the human breast carcinoma cell line MDA-MB-231. Int J Oncol. 36 (3): 737-742.
22.
go back to reference Chiu LC, Wong EY, Ooi VE: Docosahexaenoic acid modulates different genes in cell cycle and apoptosis to control growth of human leukemia HL-60 cells. Int J Oncol. 2004, 25 (3): 737-744.PubMed Chiu LC, Wong EY, Ooi VE: Docosahexaenoic acid modulates different genes in cell cycle and apoptosis to control growth of human leukemia HL-60 cells. Int J Oncol. 2004, 25 (3): 737-744.PubMed
23.
go back to reference Kim MS, Kang HJ, Moon A: Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res. 2001, 24 (4): 349-354. 10.1007/BF02975105.CrossRefPubMed Kim MS, Kang HJ, Moon A: Inhibition of invasion and induction of apoptosis by curcumin in H-ras-transformed MCF10A human breast epithelial cells. Arch Pharm Res. 2001, 24 (4): 349-354. 10.1007/BF02975105.CrossRefPubMed
24.
go back to reference Kim HJ, Vosseler CA, Weber PC, Erl W: Docosahexaenoic acid induces apoptosis in proliferating human endothelial cells. J Cell Physiol. 2005, 204 (3): 881-888. 10.1002/jcp.20351.CrossRefPubMed Kim HJ, Vosseler CA, Weber PC, Erl W: Docosahexaenoic acid induces apoptosis in proliferating human endothelial cells. J Cell Physiol. 2005, 204 (3): 881-888. 10.1002/jcp.20351.CrossRefPubMed
25.
go back to reference Miura Y, Takahara K, Murata Y, Utsumi K, Tada M, Takahata K: Docosahexaenoic acid induces apoptosis via the Bax-independent pathway in HL-60 cells. Biosci Biotechnol Biochem. 2004, 68 (11): 2415-2417. 10.1271/bbb.68.2415.CrossRefPubMed Miura Y, Takahara K, Murata Y, Utsumi K, Tada M, Takahata K: Docosahexaenoic acid induces apoptosis via the Bax-independent pathway in HL-60 cells. Biosci Biotechnol Biochem. 2004, 68 (11): 2415-2417. 10.1271/bbb.68.2415.CrossRefPubMed
26.
go back to reference Serini S, Trombino S, Oliva F, Piccioni E, Monego G, Resci F, Boninsegna A, Picci N, Ranelletti FO, Calviello G: Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression. Apoptosis. 2008, 13 (9): 1172-1183. 10.1007/s10495-008-0246-1.CrossRefPubMed Serini S, Trombino S, Oliva F, Piccioni E, Monego G, Resci F, Boninsegna A, Picci N, Ranelletti FO, Calviello G: Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression. Apoptosis. 2008, 13 (9): 1172-1183. 10.1007/s10495-008-0246-1.CrossRefPubMed
27.
go back to reference Yamagami T, Porada CD, Pardini RS, Zanjani ED, Almeida-Porada G: Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell line. Cancer Biol Ther. 2009, 8 (4): 331-337. 10.4161/cbt.8.4.7334.CrossRefPubMedPubMedCentral Yamagami T, Porada CD, Pardini RS, Zanjani ED, Almeida-Porada G: Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell line. Cancer Biol Ther. 2009, 8 (4): 331-337. 10.4161/cbt.8.4.7334.CrossRefPubMedPubMedCentral
28.
go back to reference Siddiqui RA, Jenski LJ, Harvey KA, Wiesehan JD, Stillwell W, Zaloga GP: Cell-cycle arrest in Jurkat leukaemic cells: a possible role for docosahexaenoic acid. Biochem J. 2003, 371 (Pt 2): 621-629.CrossRefPubMedPubMedCentral Siddiqui RA, Jenski LJ, Harvey KA, Wiesehan JD, Stillwell W, Zaloga GP: Cell-cycle arrest in Jurkat leukaemic cells: a possible role for docosahexaenoic acid. Biochem J. 2003, 371 (Pt 2): 621-629.CrossRefPubMedPubMedCentral
29.
go back to reference Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS: Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. Carcinogenesis. 2003, 24 (9): 1541-1548. 10.1093/carcin/bgg110.CrossRefPubMedPubMedCentral Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS: Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. Carcinogenesis. 2003, 24 (9): 1541-1548. 10.1093/carcin/bgg110.CrossRefPubMedPubMedCentral
30.
go back to reference Tanaka T, Suh KS, Lo AM, De Luca LM: p21WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid × receptor (RXR) heterodimer and RXR/RXR homodimer. J Biol Chem. 2007, 282 (41): 29987-29997. 10.1074/jbc.M701700200.CrossRefPubMed Tanaka T, Suh KS, Lo AM, De Luca LM: p21WAF1/CIP1 is a common transcriptional target of retinoid receptors: pleiotropic regulatory mechanism through retinoic acid receptor (RAR)/retinoid × receptor (RXR) heterodimer and RXR/RXR homodimer. J Biol Chem. 2007, 282 (41): 29987-29997. 10.1074/jbc.M701700200.CrossRefPubMed
31.
go back to reference Altenburg JD, Siddiqui RA: Omega-3 polyunsaturated fatty acids down-modulate CXCR4 expression and function in MDA-MB-231 breast cancer cells. Mol Cancer Res. 2009, 7 (7): 1013-1020. 10.1158/1541-7786.MCR-08-0385.CrossRefPubMed Altenburg JD, Siddiqui RA: Omega-3 polyunsaturated fatty acids down-modulate CXCR4 expression and function in MDA-MB-231 breast cancer cells. Mol Cancer Res. 2009, 7 (7): 1013-1020. 10.1158/1541-7786.MCR-08-0385.CrossRefPubMed
32.
go back to reference Srimal RC, Dhawan BN: Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol. 1973, 25 (6): 447-452.CrossRefPubMed Srimal RC, Dhawan BN: Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol. 1973, 25 (6): 447-452.CrossRefPubMed
33.
go back to reference Maheshwari RK, Singh AK, Gaddipati J, Srimal RC: Multiple biological activities of curcumin: a short review. Life Sci. 2006, 78 (18): 2081-2087. 10.1016/j.lfs.2005.12.007.CrossRefPubMed Maheshwari RK, Singh AK, Gaddipati J, Srimal RC: Multiple biological activities of curcumin: a short review. Life Sci. 2006, 78 (18): 2081-2087. 10.1016/j.lfs.2005.12.007.CrossRefPubMed
34.
go back to reference Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008, 52 (Suppl 1): S103-127.PubMed Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res. 2008, 52 (Suppl 1): S103-127.PubMed
35.
go back to reference Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV, Sarkar FH: Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem. 10 (5): 372-387. Padhye S, Chavan D, Pandey S, Deshpande J, Swamy KV, Sarkar FH: Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Mini Rev Med Chem. 10 (5): 372-387.
36.
go back to reference Patel BB, Majumdar AP: Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer. 2009, 61 (6): 842-846. 10.1080/01635580903285106.CrossRefPubMed Patel BB, Majumdar AP: Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. Nutr Cancer. 2009, 61 (6): 842-846. 10.1080/01635580903285106.CrossRefPubMed
37.
go back to reference Villegas I, Sanchez-Fidalgo S, Alarcon de la Lastra C: New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res. 2008, 52 (9): 1040-1061. 10.1002/mnfr.200700280.CrossRefPubMed Villegas I, Sanchez-Fidalgo S, Alarcon de la Lastra C: New mechanisms and therapeutic potential of curcumin for colorectal cancer. Mol Nutr Food Res. 2008, 52 (9): 1040-1061. 10.1002/mnfr.200700280.CrossRefPubMed
38.
go back to reference Shishodia S, Chaturvedi MM, Aggarwal BB: Role of curcumin in cancer therapy. Curr Probl Cancer. 2007, 31 (4): 243-305. 10.1016/j.currproblcancer.2007.04.001.CrossRefPubMed Shishodia S, Chaturvedi MM, Aggarwal BB: Role of curcumin in cancer therapy. Curr Probl Cancer. 2007, 31 (4): 243-305. 10.1016/j.currproblcancer.2007.04.001.CrossRefPubMed
39.
go back to reference Chen A, Xu J, Johnson AC: Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene. 2006, 25 (2): 278-287.PubMed Chen A, Xu J, Johnson AC: Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene. 2006, 25 (2): 278-287.PubMed
40.
go back to reference Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ: Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev. 2002, 11 (6): 535-540.PubMed Perkins S, Verschoyle RD, Hill K, Parveen I, Threadgill MD, Sharma RA, Williams ML, Steward WP, Gescher AJ: Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev. 2002, 11 (6): 535-540.PubMed
41.
go back to reference Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH: Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 1994, 54 (22): 5841-5847.PubMed Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH: Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res. 1994, 54 (22): 5841-5847.PubMed
42.
go back to reference Singh SV, Hu X, Srivastava SK, Singh M, Xia H, Orchard JL, Zaren HA: Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis. 1998, 19 (8): 1357-1360. 10.1093/carcin/19.8.1357.CrossRefPubMed Singh SV, Hu X, Srivastava SK, Singh M, Xia H, Orchard JL, Zaren HA: Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis. 1998, 19 (8): 1357-1360. 10.1093/carcin/19.8.1357.CrossRefPubMed
43.
go back to reference Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate. 2004, 60 (1): 1-17. 10.1002/pros.10359.CrossRefPubMed Dorai T, Dutcher JP, Dempster DW, Wiernik PH: Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate. 2004, 60 (1): 1-17. 10.1002/pros.10359.CrossRefPubMed
44.
go back to reference Choudhuri T, Pal S, Das T, Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 2005, 280 (20): 20059-20068. 10.1074/jbc.M410670200.CrossRefPubMed Choudhuri T, Pal S, Das T, Sa G: Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem. 2005, 280 (20): 20059-20068. 10.1074/jbc.M410670200.CrossRefPubMed
45.
go back to reference Thangapazham RL, Sharma A, Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. Aaps J. 2006, 8 (3): E443-449. 10.1208/aapsj080352.CrossRefPubMedPubMedCentral Thangapazham RL, Sharma A, Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. Aaps J. 2006, 8 (3): E443-449. 10.1208/aapsj080352.CrossRefPubMedPubMedCentral
46.
go back to reference Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G: Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 2007, 73 (7): 1024-1032. 10.1016/j.bcp.2006.12.010.CrossRefPubMed Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G: Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 2007, 73 (7): 1024-1032. 10.1016/j.bcp.2006.12.010.CrossRefPubMed
47.
go back to reference Notoya M, Nishimura H, Woo JT, Nagai K, Ishihara Y, Hagiwara H: Curcumin inhibits the proliferation and mineralization of cultured osteoblasts. Eur J Pharmacol. 2006, 534 (1-3): 55-62. 10.1016/j.ejphar.2006.01.028.CrossRefPubMed Notoya M, Nishimura H, Woo JT, Nagai K, Ishihara Y, Hagiwara H: Curcumin inhibits the proliferation and mineralization of cultured osteoblasts. Eur J Pharmacol. 2006, 534 (1-3): 55-62. 10.1016/j.ejphar.2006.01.028.CrossRefPubMed
48.
go back to reference Park MJ, Kim EH, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Choi SH, Shim BS, et al: Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol. 2002, 21 (2): 379-383.PubMed Park MJ, Kim EH, Park IC, Lee HC, Woo SH, Lee JY, Hong YJ, Rhee CH, Choi SH, Shim BS, et al: Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. Int J Oncol. 2002, 21 (2): 379-383.PubMed
49.
go back to reference Zheng S, Chen A: Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J. 2004, 384 (Pt 1): 149-157.CrossRefPubMedPubMedCentral Zheng S, Chen A: Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J. 2004, 384 (Pt 1): 149-157.CrossRefPubMedPubMedCentral
50.
go back to reference Chen YR, Tan TH: Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene. 1998, 17 (2): 173-178. 10.1038/sj.onc.1201941.CrossRefPubMed Chen YR, Tan TH: Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene. 1998, 17 (2): 173-178. 10.1038/sj.onc.1201941.CrossRefPubMed
51.
go back to reference Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G: Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 2002, 512 (1-3): 334-340. 10.1016/S0014-5793(02)02292-5.CrossRefPubMed Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G: Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 2002, 512 (1-3): 334-340. 10.1016/S0014-5793(02)02292-5.CrossRefPubMed
52.
go back to reference Squires MS, Hudson EA, Howells L, Sale S, Houghton CE, Jones JL, Fox LH, Dickens M, Prigent SA, Manson MM: Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol. 2003, 65 (3): 361-376. 10.1016/S0006-2952(02)01517-4.CrossRefPubMed Squires MS, Hudson EA, Howells L, Sale S, Houghton CE, Jones JL, Fox LH, Dickens M, Prigent SA, Manson MM: Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol. 2003, 65 (3): 361-376. 10.1016/S0006-2952(02)01517-4.CrossRefPubMed
53.
go back to reference Saw CL, Huang Y, Kong AN: Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol. 79 (3): 421-430. Saw CL, Huang Y, Kong AN: Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol. 79 (3): 421-430.
54.
go back to reference Swamy MV, Citineni B, Patlolla JM, Mohammed A, Zhang Y, Rao CV: Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer. 2008, 60 (Suppl 1): 81-89.CrossRefPubMed Swamy MV, Citineni B, Patlolla JM, Mohammed A, Zhang Y, Rao CV: Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr Cancer. 2008, 60 (Suppl 1): 81-89.CrossRefPubMed
55.
go back to reference Bowe DB, Sadlonova A, Toleman CA, Novak Z, Hu Y, Huang P, Mukherjee S, Whitsett T, Frost AR, Paterson AJ, et al: O-GlcNAc integrates the proteasome and transcriptome to regulate nuclear hormone receptors. Mol Cell Biol. 2006, 26 (22): 8539-8550. 10.1128/MCB.01053-06.CrossRefPubMedPubMedCentral Bowe DB, Sadlonova A, Toleman CA, Novak Z, Hu Y, Huang P, Mukherjee S, Whitsett T, Frost AR, Paterson AJ, et al: O-GlcNAc integrates the proteasome and transcriptome to regulate nuclear hormone receptors. Mol Cell Biol. 2006, 26 (22): 8539-8550. 10.1128/MCB.01053-06.CrossRefPubMedPubMedCentral
56.
go back to reference Heppner GH, Wolman SR: MCF-10AT: A Model for Human Breast Cancer Development. Breast J. 1999, 5 (2): 122-129. 10.1046/j.1524-4741.1999.00136.x.CrossRefPubMed Heppner GH, Wolman SR: MCF-10AT: A Model for Human Breast Cancer Development. Breast J. 1999, 5 (2): 122-129. 10.1046/j.1524-4741.1999.00136.x.CrossRefPubMed
57.
go back to reference Shekhar PV, Chen ML, Werdell J, Heppner GH, Miller FR, Christman JK: Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer. Int J Oncol. 1998, 13 (5): 907-915.PubMed Shekhar PV, Chen ML, Werdell J, Heppner GH, Miller FR, Christman JK: Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer. Int J Oncol. 1998, 13 (5): 907-915.PubMed
58.
go back to reference Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et al: The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 4: 35-41. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et al: The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 4: 35-41.
59.
go back to reference Tallarida RJ, Stone DJ, Raffa RB: Efficient designs for studying synergistic drug combinations. Life Sci. 1997, 61 (26): PL 417-425.CrossRef Tallarida RJ, Stone DJ, Raffa RB: Efficient designs for studying synergistic drug combinations. Life Sci. 1997, 61 (26): PL 417-425.CrossRef
60.
go back to reference Rodbard D: Apparent positive cooperative effects in cyclic AMP and corticosterone production by isolated adrenal cells in response to ACTH analogues. Endocrinology. 1974, 94 (5): 1427-1437. 10.1210/endo-94-5-1427.CrossRefPubMed Rodbard D: Apparent positive cooperative effects in cyclic AMP and corticosterone production by isolated adrenal cells in response to ACTH analogues. Endocrinology. 1974, 94 (5): 1427-1437. 10.1210/endo-94-5-1427.CrossRefPubMed
61.
go back to reference Lee JJ, Kong M, Ayers GD, Lotan R: Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat. 2007, 17 (3): 461-480. 10.1080/10543400701199593.CrossRefPubMed Lee JJ, Kong M, Ayers GD, Lotan R: Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat. 2007, 17 (3): 461-480. 10.1080/10543400701199593.CrossRefPubMed
62.
go back to reference Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE: Rosetta error model for gene expression analysis. Bioinformatics. 2006, 22 (9): 1111-1121.CrossRefPubMed Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE: Rosetta error model for gene expression analysis. Bioinformatics. 2006, 22 (9): 1111-1121.CrossRefPubMed
63.
go back to reference Chignell CF, Bilski P, Reszka KJ, Motten AG, Sik RH, Dahl TA: Spectral and photochemical properties of curcumin. Photochem Photobiol. 1994, 59 (3): 295-302. 10.1111/j.1751-1097.1994.tb05037.x.CrossRefPubMed Chignell CF, Bilski P, Reszka KJ, Motten AG, Sik RH, Dahl TA: Spectral and photochemical properties of curcumin. Photochem Photobiol. 1994, 59 (3): 295-302. 10.1111/j.1751-1097.1994.tb05037.x.CrossRefPubMed
64.
go back to reference Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI: Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta. 2008, 1780 (4): 673-679.CrossRefPubMed Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI: Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta. 2008, 1780 (4): 673-679.CrossRefPubMed
65.
go back to reference Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, et al: Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther. 2007, 6 (3): 820-832. 10.1158/1535-7163.MCT-06-0650.CrossRefPubMed Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, et al: Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther. 2007, 6 (3): 820-832. 10.1158/1535-7163.MCT-06-0650.CrossRefPubMed
66.
go back to reference Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ: Biological functions of maspin. J Cell Physiol. 2006, 209 (3): 617-624. 10.1002/jcp.20782.CrossRefPubMed Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ: Biological functions of maspin. J Cell Physiol. 2006, 209 (3): 617-624. 10.1002/jcp.20782.CrossRefPubMed
67.
go back to reference Khalkhali-Ellis Z, Christian AL, Kirschmann DA, Edwards EM, Rezaie-Thompson M, Vasef MA, Gruman LM, Seftor RE, Norwood LE, Hendrix MJ: Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clin Cancer Res. 2004, 10 (2): 449-454. 10.1158/1078-0432.CCR-1002-03.CrossRefPubMed Khalkhali-Ellis Z, Christian AL, Kirschmann DA, Edwards EM, Rezaie-Thompson M, Vasef MA, Gruman LM, Seftor RE, Norwood LE, Hendrix MJ: Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clin Cancer Res. 2004, 10 (2): 449-454. 10.1158/1078-0432.CCR-1002-03.CrossRefPubMed
68.
go back to reference Liu Z, Shi HY, Nawaz Z, Zhang M: Tamoxifen induces the expression of maspin through estrogen receptor-alpha. Cancer Lett. 2004, 209 (1): 55-65. 10.1016/j.canlet.2003.11.018.CrossRefPubMed Liu Z, Shi HY, Nawaz Z, Zhang M: Tamoxifen induces the expression of maspin through estrogen receptor-alpha. Cancer Lett. 2004, 209 (1): 55-65. 10.1016/j.canlet.2003.11.018.CrossRefPubMed
69.
go back to reference Androutsopoulos VP, Mahale S, Arroo RR, Potter G: Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation. Oncol Rep. 2009, 21 (6): 1525-1528.PubMed Androutsopoulos VP, Mahale S, Arroo RR, Potter G: Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation. Oncol Rep. 2009, 21 (6): 1525-1528.PubMed
70.
go back to reference Androutsopoulos VP, Ruparelia K, Arroo RR, Tsatsakis AM, Spandidos DA: CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology. 2009, 264 (3): 162-170. 10.1016/j.tox.2009.07.023.CrossRefPubMed Androutsopoulos VP, Ruparelia K, Arroo RR, Tsatsakis AM, Spandidos DA: CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology. 2009, 264 (3): 162-170. 10.1016/j.tox.2009.07.023.CrossRefPubMed
71.
go back to reference Ware WR: Nutrition and the prevention and treatment of cancer: association of cytochrome P450 CYP1B1 with the role of fruit and fruit extracts. Integr Cancer Ther. 2009, 8 (1): 22-28. 10.1177/1534735408328573.CrossRefPubMed Ware WR: Nutrition and the prevention and treatment of cancer: association of cytochrome P450 CYP1B1 with the role of fruit and fruit extracts. Integr Cancer Ther. 2009, 8 (1): 22-28. 10.1177/1534735408328573.CrossRefPubMed
72.
go back to reference Ware WR: P450 CYP1B1 mediated fluorescent tumor markers: a potentially useful approach for photodynamic therapy, diagnosis and establishing surgical margins. Med Hypotheses. 2009, 72 (1): 67-70. 10.1016/j.mehy.2008.07.054.CrossRefPubMed Ware WR: P450 CYP1B1 mediated fluorescent tumor markers: a potentially useful approach for photodynamic therapy, diagnosis and establishing surgical margins. Med Hypotheses. 2009, 72 (1): 67-70. 10.1016/j.mehy.2008.07.054.CrossRefPubMed
73.
go back to reference Cheah YH, Nordin FJ, Sarip R, Tee TT, Azimahtol HL, Sirat HM, Rashid BA, Abdullah NR, Ismail Z: Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231. Cancer Cell Int. 2009, 9: 1-10.1186/1475-2867-9-1.CrossRefPubMedPubMedCentral Cheah YH, Nordin FJ, Sarip R, Tee TT, Azimahtol HL, Sirat HM, Rashid BA, Abdullah NR, Ismail Z: Combined xanthorrhizol-curcumin exhibits synergistic growth inhibitory activity via apoptosis induction in human breast cancer cells MDA-MB-231. Cancer Cell Int. 2009, 9: 1-10.1186/1475-2867-9-1.CrossRefPubMedPubMedCentral
74.
go back to reference Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21 (4B): 2895-2900.PubMed Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001, 21 (4B): 2895-2900.PubMed
75.
go back to reference Rusca A, Di Stefano AF, Doig MV, Scarsi C, Perucca E: Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur J Clin Pharmacol. 2009, 65 (5): 503-510. 10.1007/s00228-008-0605-4.CrossRefPubMed Rusca A, Di Stefano AF, Doig MV, Scarsi C, Perucca E: Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur J Clin Pharmacol. 2009, 65 (5): 503-510. 10.1007/s00228-008-0605-4.CrossRefPubMed
76.
go back to reference Calviello G, Di Nicuolo F, Serini S, Piccioni E, Boninsegna A, Maggiano N, Ranelletti FO, Palozza P: Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol. 2005, 55 (1): 12-20. 10.1007/s00280-004-0846-6.CrossRefPubMed Calviello G, Di Nicuolo F, Serini S, Piccioni E, Boninsegna A, Maggiano N, Ranelletti FO, Palozza P: Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother Pharmacol. 2005, 55 (1): 12-20. 10.1007/s00280-004-0846-6.CrossRefPubMed
77.
go back to reference Narayanan NK, Narayanan BA, Bosland M, Condon MS, Nargi D: Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Int J Cancer. 2006, 119 (7): 1586-1598. 10.1002/ijc.22031.CrossRefPubMed Narayanan NK, Narayanan BA, Bosland M, Condon MS, Nargi D: Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Int J Cancer. 2006, 119 (7): 1586-1598. 10.1002/ijc.22031.CrossRefPubMed
78.
go back to reference Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O: Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer. 2009, 101 (12): 1978-1985. 10.1038/sj.bjc.6605441.CrossRefPubMedPubMedCentral Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O: Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer. 2009, 101 (12): 1978-1985. 10.1038/sj.bjc.6605441.CrossRefPubMedPubMedCentral
79.
go back to reference Yadav S, Singhal NK, Singh V, Rastogi N, Srivastava PK, Singh MP: Association of single nucleotide polymorphisms in CYP1B1 and COMT genes with breast cancer susceptibility in Indian women. Dis Markers. 2009, 27 (5): 203-210.CrossRefPubMedPubMedCentral Yadav S, Singhal NK, Singh V, Rastogi N, Srivastava PK, Singh MP: Association of single nucleotide polymorphisms in CYP1B1 and COMT genes with breast cancer susceptibility in Indian women. Dis Markers. 2009, 27 (5): 203-210.CrossRefPubMedPubMedCentral
Metadata
Title
A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone
Authors
Jeffrey D Altenburg
Andrew A Bieberich
Colin Terry
Kevin A Harvey
Justin F VanHorn
Zhidong Xu
V Jo Davisson
Rafat A Siddiqui
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-149

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine